Abstract: This invention relates to a drug delivery vehicle for penetrating the Blood-Brain Barrier (BBB). Said drug delivery vehicle is a cube-structured nanostructure formed from a double-stranded deoxyribonucleic acid (DNA) framework, specifically D-form DNA. This drug delivery vehicle forms a protein corona on its surface within the serum, and through this, it passes the BBB via receptor-mediated transcytosis. The present invention provides a drug delivery vehicle for the purpose of being loaded with drugs, such as antisense oligonucleotides (ASOs), to deliver them to brain tissue for the treatment of brain tumors like glioblastoma.

Abstract: The present invention relates to a liver-specific drug delivery carrier comprising a nucleic acid nanoparticle and cholesterol; a liver-specific complex; a pharmaceutical composition for prevention or treatment of liver disease using the same; and a method for preventing or treating liver disease.

Abstract: The present invention relates to three-dimensional self-assembled nucleic acid nanoparticles, a drug delivery system comprising the same, and a pharmaceutical composition for the prevention or treatment of acute kidney injury, which comprises the same. The three-dimensional self-assembled nucleic acid nanoparticles of the present invention, which have a tetrahedral structure, exhibit an excellent renal-targeting ability, and thus the nanoparticles conjugated with the pharmaceutically active ingredient for p53 exhibit excellent p53 and caspase 3 expression reductions in vitro and in vivo, and can thereby be applied to the prevention or treatment of acute kidney injury.

Abstract: The present invention relates to a novel trans-activating CRISPR RNA (tracrRNA) including a fragment of a tracrRNA, and a gRNA, a CRISPR-Cas9 system, and a kit including the tracrRNA.

Abstract: The present invention relates to a lung-specific drug delivery system consisting of oligonucleotide polymers and biocompatible cationic peptides for the prevention or treatment of pulmonary fibrosis, and a use thereof. The drug delivery system according to the present invention can be specifically accumulated in the lungs and absorbed into lung fibrotic cells to knock down TGF-?, thereby preventing or treating pulmonary fibrosis.

Abstract: The present invention relates to three-dimensional self-assembled nucleic acid nanoparticles, a drug delivery system comprising the same, and a pharmaceutical composition for the prevention or treatment of acute kidney injury, which comprises the same. The three-dimensional self-assembled nucleic acid nanoparticles of the present invention, which have a tetrahedral structure, exhibit an excellent renal-targeting ability, and thus the nanoparticles conjugated with the pharmaceutically active ingredient for p53 exhibit excellent p53 and caspase 3 expression reductions in vitro and in vivo, and can thereby be applied to the prevention or treatment of acute kidney injury.

Abstract: The present invention relates to a drug carrier having L-DNA nanocage structure prepared by using L-DNA, the mirror form of natural DNA, as a backbone. The drug carrier of the present invention has very superior cellular uptake efficiency and serum stability, so that it can be applied to deliver various drugs into cells usefully.

Abstract: The present invention relates to a drug carrier having L-DNA nanocage structure prepared by using L-DNA, the mirror form of natural DNA, as a backbone. The drug carrier of the present invention has very superior cellular uptake efficiency and serum stability, so that it can be applied to deliver various drugs into cells usefully.

Abstract: The present invention relates to a modified nucleotide and real-time polymerase reaction using the nucleotide. Specifically, the present invention relates to a fluorescence material linked-nucleotide, a composition for real-time polymerase reaction comprising the nucleotide, an analysis kit and an analysis method. In the present invention, the fluorescence material linked-nucleotide serves the dual roles of producing fluorescence signal as well as being used as a substrate. Therefore, the present invention is economically advantageous because it is unnecessary to prepare probes, but can be applied to analyze various real-time polymerase reactions such as PCR, RCA and isothermal polymerization reaction, and shows higher quality of performance than the past methods.

Abstract: The present invention relates to a DNA sequencing method using a nucleoside triphosphate with a fluorescent blocking group on its 3?-OH end as a reversible terminator. Further, the present invention relates to sequencing-by-synthesis method using the mono-modified reversible terminator (MRT), the novel nucleotide monomer having a reversible fluorescent blocking group removable chemically or enzymatically at its 3?-OH end. The sequencing method of the present invention facilitates sequencing of bases inserted by terminating extension of a nucleotide chain by the nucleotide monomer and then detecting fluorescence signal from 3?-OH end. At this time, after analyzing the fluorescence signal, the blocking group conjugated to the 3?-OH end can be effectively removed, indicating that a free 3?-OH functional group can be successfully restored, so that the next monomer insertion is possible, making continuous sequencing possible.

Abstract: The present invention relates to a DNA sequencing method using a nucleoside triphosphate with a fluorescent blocking group on its 3?-OH end as a reversible terminator. Further, the present invention relates to sequencing-by-synthesis method using the mono-modified reversible terminator (MRT), the novel nucleotide monomer having a reversible fluorescent blocking group removable chemically or enzymatically at its 3?-OH end. The sequencing method of the present invention facilitates sequencing of bases inserted by terminating extension of a nucleotide chain by the nucleotide monomer and then detecting fluorescence signal from 3?-OH end. At this time, after analyzing the fluorescence signal, the blocking group conjugated to the 3?-OH end can be effectively removed, indicating that a free 3?-OH functional group can be successfully restored, so that the next monomer insertion is possible, making continuous sequencing possible.

Abstract: An antigen detection kit and an antigen detection method using the same are provided. The antigen detection kit comprises a capture antibody, a detection antibody bound to a single stranded DNA oligonucleotide, a single stranded RNA oligonucleotide complementary sequence to the DNA oligonucleotide, and an RNase.

Abstract: A method for quantitative analysis of interactions between fluorescein-labeled HIF-1? (alpha) C-terminal peptides and cAMP-responsive element binding protein (CBP) or p300 proteins, and a method of screening inhibitors against the formation of HIF-1?-p300 or HIF-1?-CBP protein complexes using the above method is described.

Abstract: The present invention provides a plasmid for expressing a thioredoxin fusion protein comprising thioredoxin as a fusion partner, an E. coli cell transformed with the plasmid, and an efficient method for producing a target protein using the E. coli cell. The method according to the present invention can easily remove thioredoxin from thioredoxin fusion protein, so that can produce a target protein of interest in pure and large quantities in the field of medicine and bioengineering.

Abstract: A method and a kit for detecting a target protein in a sample with a signal amplification strategy are provided. The signal amplification strategy is established for the aptamer-based molecular recognition of a target protein with concomitant release of single-stranded DNA (G-DNA), which binds complementarily to a single-stranded RNA comprising a fluorophore and a quencher (“F-RNA-Q”). The fluorescence-quenched RNA is then degraded by RNase H to result in a fluorescence signal, and the undamaged G-DNA is recycled to yield fluorescence amplification.

Abstract: The present invention relates to a method for quantitative analysis of interactions between fluorescein-labeled HIF-1? (alpha) C-terminal peptides and cAMP-responsive element binding protein (CBP) or p300 proteins, and a method of screening inhibitors against the formation of HIF-1?-p300 or HIF-1?-CBP protein complexes using the above method. Therefore, the fluorescence polarization (FP) measurement method of the present invention is useful for systemically evaluating the HIF-1?-CBP or HIF-1?-p300 interactions, and examining the effects of posttranslational modifications (hydroxylation, S-nitrosylation, and phosphorylation) of the C-TAD peptide of HIF-1? on the recruitment of p300.

Abstract: A method and a kit for detecting a target protein in a sample with a signal amplification strategy are provided. The signal amplification strategy is established for the aptamer-based molecular recognition of a target protein with concomitant release of single-stranded DNA (G-DNA), which binds complementarily to a single-stranded RNA comprising a fluorophore and a quencher (“F-RNA-Q”). The fluorescence-quenched RNA is then degraded by RNase H to result in a fluorescence signal, and the undamaged G-DNA is recycled to yield fluorescence amplification.